Thomas R. Staab II
Thomas R. Staab II's purchase track record
Thomas R. Staab II has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/11/2026 | TENX | $11K | pending | pending | — |
| 12/6/2022 | LNSR | $9K | -2.8% | -0.3% | +8.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Lucid Capital Markets Begins Coverage of LENSAR, Sets $11 Target. Lucid Capital Markets has started coverage on LENSAR and issued a positive rating. The firm set a price target of $11, which sits near the upper end of the company’s 52‑week range. The new outlook may attract attention from investors looking at LENSAR’s valuation relative to its peers. The coverage adds a fresh perspective to the market’s view of the stock.
Transaction History
| TENX | ▲ Buy | Open Market | 5,675 | $11K | 9/11/2026 | View on chart |
| TENX | ▲ Buy | Grant | 10,000 | $0 | 5/11/2026 | View on chart |
| LNSR | ▼ Sell | Tax Withholding | 1,350 | $7K | 5/6/2026 | View on chart |
| LNSR | ▲ Buy | Option Exercise | 5,500 | $15K | 3/19/2026 | View on chart |
| LNSR | ▼ Sell | Tax Withholding | 1,076 | $12K | 2/18/2026 | View on chart |
| LNSR | ▼ Sell | Tax Withholding | 1,826 | $21K | 1/11/2026 | View on chart |
| LNSR | ▲ Buy | Grant | 12,766 | $0 | 2/18/2025 | View on chart |
| LNSR | ▼ Sell | Tax Withholding | 1,839 | $15K | 1/11/2025 | View on chart |
| LNSR | ▲ Buy | Option Exercise | 3,500 | $9K | 8/8/2024 | View on chart |
| LNSR | ▲ Buy | Grant | 19,000 | $0 | 5/6/2024 | View on chart |
| LNSR | ▼ Sell | Tax Withholding | 1,853 | $8K | 1/11/2024 | View on chart |
| LNSR | ▲ Buy | Grant | 6,656 | $0 | 1/11/2023 | View on chart |
| LNSR | ▲ Buy | Open Market | 727 | $2K | 12/7/2022 | View on chart |
| LNSR | ▲ Buy | Open Market | 2,025 | $6K | 12/6/2022 | View on chart |
| LNSR | ▲ Buy | Grant | 15,000 | $0 | 1/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Tenax Pauses TNX-103 Trial Enrollment, Seeks FDA Meeting
Tenax Therapeutics has temporarily paused enrollment in its LEVEL-2 trial for TNX-103 to amend study criteria. The company has also requested a meeting with the FDA to discuss these changes. This development is significant as it involves a key clinical trial, and the stock is currently trading near its 52-week low.
Tenax Pauses TNX-103 Trial Enrollment, Seeks FDA Meeting. Tenax Therapeutics has temporarily paused enrollment in its LEVEL-2 trial for TNX-103 to amend study criteria. The company has also requested a meeting with the FDA to discuss these changes. This development is significant as it involves a key clinical trial, and the stock is currently trading near its 52-week low.